closer look at what’s really happening when depression doesn’t respond to treatment — and what might still work.
If you’ve been told you have treatment-resistant depression, you probably know the feeling that comes with it.
It isn’t quite hopelessness. It’s something more specific. A kind of quiet, professional disappointment — usually delivered in a room with fluorescent lighting, after the fourth or fifth medication trial, by a clinician who has clearly run out of ideas. We’ll try one more. If this one doesn’t work, we may need to think about something more aggressive.
The label sticks. You start to wonder whether your brain is somehow different. Broken in a way the standard tools can’t reach. You read the statistics — about a third of patients don’t respond to standard antidepressant treatment — and you fit yourself into that number.
The label, in many cases, is wrong.
Not entirely. Treatment-resistant depression is a real clinical entity, and for some patients it genuinely describes what’s happening. But in a substantial portion of cases, the resistance isn’t in the patient. It’s in the diagnosis, the treatment plan, or the assumptions underneath both.
Here’s what tends to be going on when depression “doesn’t respond” — and why the label deserves a second look before anyone accepts it as permanent.
The diagnosis was incomplete
The single most common reason depression doesn’t respond to antidepressants is that what looks like depression is actually something else, or something more.
Bipolar spectrum illness is the most frequent culprit. A significant share of patients diagnosed with major depression actually have a bipolar pattern that hasn’t been recognized — sometimes because the hypomanic episodes were brief, productive, or felt like good months rather than symptoms. Antidepressants alone, given to someone with bipolar depression, often produce exactly the picture of treatment resistance: partial response, then return of symptoms, then mood instability, then medication after medication that doesn’t quite work.
ADHD is another common one. Adults with undiagnosed ADHD often present with symptoms that look identical to depression — low motivation, difficulty concentrating, fatigue, irritability, a sense of failure. Standard antidepressants don’t help much because they’re treating the wrong condition. Stimulant treatment for ADHD frequently brings dramatic relief — not because it “fixed the depression,” but because the depression was never quite what it appeared to be.
Trauma is the third. PTSD and complex trauma often masquerade as depression in primary care settings. The mood symptoms are real, but they’re downstream of something the antidepressant isn’t built to address. Trauma-focused therapy frequently moves the needle in ways that years of medication changes couldn’t.
A careful psychiatric evaluation often uncovers one of these patterns within a single conversation. Years of “resistance” sometimes resolve when the actual diagnosis comes into focus.
The medication trials weren’t really adequate
This one is uncomfortable to discuss, because it implicates the clinical system rather than the patient. But it’s worth being honest about.
For a medication trial to “count” toward treatment resistance, several things have to be true. The dose has to reach the therapeutic range. The trial has to last long enough for the medication to take full effect — generally six to eight weeks at the right dose, not two weeks at the starting dose. The patient has to actually take it as prescribed. And the response has to be assessed carefully, ideally with validated symptom scales rather than a quick “how are you feeling?” at the end of a very brief visit.
In practice, a lot of medication trials don’t meet that bar. Doses get raised too slowly, or never quite reach therapeutic levels. Trials get cut short when side effects appear in the first two weeks — a period when side effects are common and usually temporary, but mood improvement hasn’t yet had time to develop. Switching happens reactively rather than strategically.
When someone has been on six medications without relief, the relevant question often isn’t “why didn’t the medications work?” It’s “did any of them actually get a fair trial?” Sometimes the answer is yes, and the resistance is real. Often, the answer is no — and the right next step isn’t a more exotic treatment but a properly conducted trial of something already familiar.
Something medical is in the way
Depression doesn’t happen in a vacuum. The brain sits inside a body, and the body has a great deal of influence over mood.
Thyroid dysfunction is a frequent contributor and a frequently missed one — particularly in patterns where standard thyroid labs look “normal” but the picture clinically suggests otherwise. Anemia, vitamin D deficiency, B12 deficiency, and chronic inflammation all affect mood and energy in ways that can mimic or worsen depression. Sleep apnea is especially common as a hidden driver: untreated, it produces fatigue, brain fog, irritability, and low mood that no antidepressant will adequately reach.
Hormonal changes — perimenopause, postpartum shifts, low testosterone — can produce or amplify depressive symptoms in ways that don’t respond well to antidepressants alone but improve substantially with appropriate medical treatment.
A psychiatric evaluation that doesn’t check for these things isn’t really an evaluation. It’s a triage. And patients labeled treatment-resistant on the basis of incomplete workups deserve a more thorough look before the label is accepted.
Something in the environment is driving it
Some depression is biological. Some is situational. Most is both. But medications work on the biological component, and they don’t do much about the situational one.
A patient in an abusive relationship, a punishing job, a financial crisis, or a chronic caregiving role isn’t necessarily failing to respond to medication. They may be responding fully — and still depressed, because the medication is working against a current that’s stronger than it is.
This isn’t about blame or about telling people to just change their circumstances. It’s about acknowledging that depression sometimes has causes that medication cannot reach, and that the right response in those cases isn’t a more aggressive medication strategy. It’s therapy, support, structural change, or sometimes simply a long enough pause from the source of stress to let the system recover.
The medication is working — but other things aren’t
A frequent and underdiscussed pattern: the medication is doing what it should, but sleep is terrible, exercise is nonexistent, alcohol use is heavy, social isolation is profound, or untreated anxiety is undermining everything else. The depression score barely moves because the foundation underneath it is collapsing faster than the medication can build.
In these cases, adding a sixth medication doesn’t help. What helps is a coordinated plan — sleep treatment, substance use assessment, anxiety treatment, behavioral activation, social connection — that lets the medication actually do its work.
When it really is treatment-resistant
All of this said, some patients have done everything right. The diagnosis is accurate. The trials have been adequate. The medical workup is clean. The therapy has been the right kind. The lifestyle factors are in order. And the depression still hasn’t lifted.
This is where modern psychiatry has the most to offer.
Treatment-resistant depression — the real, properly identified kind — now has options that didn’t exist a decade ago. Transcranial magnetic stimulation (TMS) uses focused magnetic pulses to stimulate brain regions involved in mood, with FDA clearance for treatment-resistant depression since 2008 and accelerated protocols that can deliver a full course in days rather than weeks. Spravato (esketamine) is an FDA-approved nasal spray that works through the glutamate system — a pathway entirely different from traditional antidepressants. Ketamine therapy, used carefully and in appropriate clinical settings, has shown rapid benefit for some forms of severe depression that haven’t responded to anything else.
These are not last-ditch experiments. They’re well-studied, increasingly insurance-covered treatments that have changed what’s possible for patients who genuinely needed something different.
But — and this is the point — they work best when they’re given to patients who truly need them. Not patients labeled resistant after three rushed medication trials and a missed diagnosis. Patients whose treatment resistance has been carefully established, whose other contributors have been addressed, and whose advanced treatment is part of a thoughtful plan rather than a desperate one.
The takeaway
If you’ve been told you have treatment-resistant depression, the most important thing you can do is take the label seriously enough to question it.
Has your diagnosis been carefully re-examined? Have your prior medication trials really been adequate? Has the medical workup been thorough? Are sleep, hormones, trauma, substance use, ADHD, and bipolar spectrum patterns all genuinely on the table? Has the rest of your life been supported in ways that let the medication work?
If yes — then advanced treatments like TMS, Spravato, and ketamine therapy may well be the right next step, and modern psychiatry has more to offer you than at any other point in history.
If not — then “treatment-resistant” may be the wrong word for what’s happening. And the right next step might be a different kind of evaluation, with a clinician willing to slow down and look at the whole picture before assuming nothing else will work.
Most depression has a way forward. Sometimes it’s just a matter of being looked at carefully enough to find it.
Goldstone Psychiatry & Neuromodulation Center offers modern, personalized psychiatric care — including Treatment-Resistant Depression Consultations, Second-Opinion & Diagnostic Clarification, and Advanced Treatments for Depression that hasn’t responded to standard approaches.
No comment